Has John Parker, MD received payments from drug or device companies?

Yes. Drug and device makers reported $4,141,834 in general payments to John Parker, MD across 1,932 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean John Parker, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about John Parker, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

John Parker, MD

Endocrinology, Diabetes & Metabolism · Wilmington, NCNPI 1457345928

Payments from drug & device makers

$4,141,834in general payments, 2019–2025

Across 1,932 payments — averaging $2143.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Eli Lilly$2.3M
AbbVie$596K
Pfizer$590K
Corcept Therapeutics$174K
Novo Nordisk AS$105K
AstraZeneca$81K
plus $344K from 54 others

$41,511in research payments, 2019–2025

Across 24 payments — averaging $1729.64 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Eli Lilly$40K
Corcept Therapeutics$1K
Novo Nordisk AS$420

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Eli Lilly	66	$2,251,153
AbbVie	29	$596,287
Pfizer	107	$590,323
Corcept Therapeutics	150	$173,926
Novo Nordisk AS	267	$105,495
AstraZeneca	121	$80,963
Gilead	27	$78,878
Novo Nordisk	209	$53,461
BD	2	$49,660
Insulet Corporation	67	$42,991
Bayer	39	$32,977
Tolmar, Inc.	16	$31,629
Radius Health, Inc.	30	$11,847
Boehringer Ingelheim Pharma GmbH & Co.kg	67	$9,124
Boehringer Ingelheim	47	$7,782
Esperion Therapeutics, Inc.	16	$6,651
Sanofi US Services Inc.	2	$2,318
Merck	49	$2,256
Janssen Research & Development, LLC	1	$2,127
Dexcom, Inc.	5	$2,069
Lilly USA, LLC	123	$1,710
Amgen(2 entities)	103	$1,429
Sanofi-aventis U.S. LLC	70	$1,328
Abbott	74	$1,164
Antares Pharma, Inc.	46	$886
IBSA Pharma Inc.	24	$378
Xeris Pharmaceuticals, Inc.	14	$246
Amarin Pharma, Inc.	15	$216
Tandem Diabetes Care, Inc.	11	$194
Novartis	9	$192
Cequr Corporation	4	$164
Ascendis Pharma Endocrinology Inc	7	$161
Ultragenyx Pharmaceutical Inc.	8	$158
Amneal Pharmaceuticals LLC	9	$152
Eisai Inc.	17	$132
Kyowa Kirin, Inc.	6	$129
Recordati_rare_diseases_inc.	6	$127
Johnson & Johnson	12	$118
Azurity Pharmaceuticals, Inc.	4	$78
Shire North American Group Inc	5	$72
Valeritas, Inc.	4	$69
Averitas Pharma Inc.	2	$63
Neurocrine Biosciences, Inc.	2	$52
Senseonics, Incorporated	2	$51
Chiesi USA, Inc.	2	$49
Mannkind Corporation	3	$49
Sequel Med Tech, LLC	2	$48
Regeneron Healthcare Solutions, Inc.	3	$47
Takeda Pharmaceuticals U.S.A., Inc.	3	$45
Rhythm Pharmaceuticals, Inc.	2	$43
Ascensia Diabetes Care US Inc.	2	$40
Nalpropion Pharmaceuticals LLC	3	$40
Soleno Therapeutics, Inc.	2	$37
Medtronic	2	$31
Acella Pharmaceuticals, LLC	2	$29
Currax Pharmaceuticals LLC	2	$26
Acerus Pharmaceuticals Corporation	1	$22
Astellas Pharma US Inc	1	$19
Halozyme Inc	1	$18
Verity Pharmaceuticals Inc.	1	$18

How this compares

$4,141,834 in reported general payments places this provider in the 95th percentile of 232 endocrinology, diabetes & metabolism providers in North Carolina.

See all endocrinology, diabetes & metabolism providers in North Carolina →

Medicare billing

Part B allowed, 2024

$505,310

Medicare patients

958

Services billed

29,135

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Wilmington

Michael FavoritoWilmington$723K
Seth BraunsteinWilmington$134K
Lauren GratianWilmington$34K
Kathryn LucasMorehead City$37.9M
Mark WarrenGreenville$5M
Mary LawrenceMorehead City$4.9M
John BuseChapel Hill$3.8M
Wendy LaneAsheville$1.9M
Anthony BarberHickory$1.4M
Klara KleinChapel Hill$1.3M

See the full list for North Carolina →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →